Ultragenyx’s Angelman Phase 3 Miss Triggers Review and Cost-Cutting on September 03, 2026 Angelman Syndrome apazunersen Bayley-4 GTX-102 Infrequent MDRI Ultragenyx +
RA Capital Launches Rare Disease Company Oak Hill Bio onto Nasdaq via SPAC on July 28, 2026 Angelman Syndrome Antisense Oligonucleotides Capital Infrequent merger Nasdaq NDA Oak Hill Bio OAKH OHB-724 Phase 3 RACC Research Alliance Corporation III Rheumatoid Arthritis Rugonersen Series A financing SPAC ticker +